Navigation Links
MIGENIX Corporate Update and Requisition of Special Meeting
Date:7/8/2008

ld territories. We expect a license agreement or agreements with up-front payment(s), milestones and royalty terms to be completed after positive Phase III clinical trial results. Analysts publishing research on Cadence Pharmaceuticals have forecast annual US sales of Omigard(TM) of up to $250 million. Sales in global markets outside of the US would increase the annual sales potential.

CLS001 (2.5% topical omiganan pentahydrocloride for dermatological applications): This program is at the end of Phase II stage of development and is funded completely by our dermatology partner - Cutanea Life Sciences. Cutanea has completed an end of Phase II meeting with the FDA and plans to initiate a Phase III clinical trial in 2008 to treat rosacea. Upon successful completion of various milestones in this program (starting with Phase III enrollment), we can receive up to US$21MM in development and commercialization milestone payments and a single-digit royalty on net sales.

Celgosivir (oral alpha-glucosidase inhibitor for Hepatitis C Virus infections): A Phase II study assessing 400 mg celgosivir for tolerability, pharmacokinetics and viral kinetics when combined with the standard of care drugs, pegylated interferon alfa-2b plus ribavirin, as compared to the standard of care drugs alone for up to 12 weeks of therapy in treatment-naive HCV infected genotype 1 patients is in the final stages of completion. Results from the study are expected in the next several weeks. A previous Phase II study in non-responder genotype 1 patients provided proof of concept in that HCV patient population (see April 11, 2007 news release and January 31, 2008 Management Discussion & Analysis). The Company is currently in key strategic discussions for the partnering and advancement of celgosivir.

MX-2401 (injectable lipopeptide for serious gram positive bacterial infections): This pre-clinical compound is expected to be our next clinical candidate. Pre-clinical studies demonstrate th
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
3. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
7. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
8. MIGENIX releases CEO message #22
9. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
11. MIGENIX Appoints Pieter Dorsman to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... shipping products for cells and tissues  ("BioLife" or ... 2015 Annual Meeting of Stockholders on May 4, 2015 ... for the Annual Meeting represents a change of more ...
(Date:12/24/2014)... 23, 2014 On Friday, December ... 83, the Omnibus and Continuing Resolution Appropriations Act ... hydrocephalus a condition eligible to receive funding through ... by the Department of Defense (DoD). The Hydrocephalus ... on Capitol Hill, is celebrating this victory for ...
(Date:12/24/2014)... Pipette.com announces their Holiday in the ... their #HolidayInTheLab pictures for a chance to win pipette-themed ... those struggling to think of a holiday gift for ... Lab Contest provides the ideal holiday presents. The #HolidayInTheLab ... pictures of their chemistree, holiday sweaters, as well as ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... (OTC Bulletin Board: PHST), a leading provider of ... drug,development, today announced that its Board of Directors ... Company,s stock, to take effect at 5:00,p.m., Eastern ... will,begin trading on a reverse split-adjusted basis under ...
... NEW YORK, Nov. 12 Informed Medical Communications,(IMC), ... service,companies, today named Charles T. Saldarini to its ... CEO, Steven K. Budd, from the company,s,headquarters in ... IMC an extensive history of entrepreneurial,innovation in the ...
... November 12 The Danish biotech cluster,known as ... into a global,hotspot in the field of personalized ... pharma and big biotech. Experience Danish,competencies at the ... 12th - 13th November. With over 10 ...
Cached Biology Technology:Pharsight Announces 1-For-3 Reverse Stock Split 2Pharsight Announces 1-For-3 Reverse Stock Split 3Informed Medical Communications Appoints Charles T. Saldarini to Board of Directors 2Danish Hotspot in Personalized Medicine 2
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... LAFAYETTE, Ind. - Large hypoxic zones low in oxygen ... aquatic life, but a Purdue University study shows that ... not all species are impacted equally. Tomas Höök, ... former Purdue postdoctoral researcher Kristen Arend used output from ...
... the University of California, Riverside have found chemical evidence ... were oxygen-free and, surprisingly, contained abundant hydrogen sulfide in ... that ample hydrogen sulfide in the ocean was possible ... , a professor of biogeochemistry and the senior investigator ...
... within the brain,s neocortex lies a subnetwork of highly ... networks. Like Facebook, these neuronal networks have a small ... more information than the majority of other members, says ... Mellon and a member of the Center for the ...
Cached Biology News:Lake Erie hypoxic zone doesn't affect all fish the same, study finds 2Oxygen-free early oceans likely delayed rise of life on planet 2Oxygen-free early oceans likely delayed rise of life on planet 3Carnegie Mellon researchers identify 'Facebook neurons' 2Carnegie Mellon researchers identify 'Facebook neurons' 3
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Request Info...
Biology Products: